Society of Nuclear Medicine announces collaborative working agreement with Bio-Imaging Technologies

October 26, 2005

RESTON, Va.--The Society of Nuclear Medicine has established a collaborative working agreement with Bio-Imaging Technologies Inc., the world's largest independent, dedicated provider of medical image management for clinical trials. Together, SNM and Bio-Imaging will work in establishing multicenter clinical trial capabilities and educational programs.

"Over the last few years the society recognized the need to have nuclear medicine--and in particular PET imaging--used in more clinical trials. We have also recognized the need to help further this technology for drug development," said SNM President Peter S. Conti, M.D., Ph.D. "As we developed this concept, we looked for an experienced imaging core lab to help support our endeavors and to collaborate in this process. Bio-Imaging has a reputation of operational and scientific experience, and we are pleased to invite them to work with the Society of Nuclear Medicine," added Conti, a professor of radiology, clinical pharmacy and biomedical engineering at the University of Southern California, Los Angeles.

"This important collaboration will help the continued success of nuclear medicine in clinical practice, in drug development and in the emerging molecular imaging field," agreed SNM Vice President-Elect Alexander J. McEwan, M.D., chair of the society's Molecular Imaging and Radionuclide Therapy Trials.

Mark L. Weinstein, president and chief executive officer of Bio-Imaging, noted, "We are very pleased that SNM has chosen to partner with us. We have appreciated the role of nuclear medicine imaging in the drug and medical device development process for some time, and this will allow us to become more involved in an area that is growing and developing rapidly."

"We believe nuclear medicine utilization will continue to grow and become more acceptable to the Food and Drug Administration (FDA) for assessing the efficacy and safety of new drugs, biologics and medical devices," added Colin G. Miller, Ph.D., Bio-Imaging senior vice president of business development. "Through this collaboration, access to the expertise within the society will also allow us to expand the group of experts and consultants who provide support to our clients. Furthermore, we have identified a number of discrete initiatives on which we are starting to collaborate that will enhance our experience and help develop the use of nuclear medicine in clinical trials. Bio-Imaging education programs are also an area of collaboration with SNM," said Miller.
-end-
About the Society of Nuclear Medicine

The Society of Nuclear Medicine is an international scientific and professional organization of more than 16,000 members dedicated to promoting the science, technology and practical applications of nuclear medicine and molecular imaging to diagnose, manage and treat diseases in women, men and children. Founded more than 50 years ago, SNM continues to train physicians, technologists, scientists, physicists, chemists and radiopharmacists in state-of-the-art imaging procedures and advances; provide essential resources for health care practitioners and patients; publish the most prominent peer-reviewed resource in the field of nuclear and molecular imaging: The Journal of Nuclear Medicine; sponsor research grants, fellowships and awards; and host the premiere nuclear medicine annual meeting. SNM members have developed--and continue to explore--biological and technological innovations in medicine to look noninvasively into the molecular basis of diseases to benefit countless generations of patients. SNM is based in Reston, Va.; additional information can be found online at http://www.snm.org.

About Bio-Imaging Technologies Inc.

Bio-Imaging Technologies Inc. is a health care contract service organization providing services that support the product development process of the pharmaceutical, biotechnology and medical device industries. The company has specialized in assisting its clients in the design and management of the medical-imaging component of clinical trials since 1990. Bio-Imaging serves its clients on a global basis through its US Core Lab in Newtown, PA, its European Core Lab in Leiden, The Netherlands, and business offices in Massachusetts, the United Kingdom and Germany. Through its CapMed division, Bio-Imaging provides the Personal HealthKey™ technology and the Personal Health Record (PHR) software allowing patients to better monitor and manage their health care information.

Society of Nuclear Medicine

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.